Published on October 29, 2009 at 4:34 AM
Research and Markets (http://www.researchandmarkets.com/research/1295af/commercial_insight) has announced the addition of the "Commercial Insight: Antidiabetics - DPP-IV Inhibitors Poised to Sweep the Market" report to their offering.
Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.
Scope
- Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.
- Event-driven updated sales forecasts for 2009-18 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the diabetes market.
Highlights of this title
- The antidiabetics market in the seven major markets is expected to grow from $20 billion in 2007 to $38 billion in 2018 at a rate of 6.5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.
- In 2008, four major insulin therapies dominated the insulin market. This situation is not expected to change throughout the forecast period as there is very limited activity within the insulin antidiabetic pipeline and no serious challenges to the market leading therapies.
- The strong market position of Avandia in 2007 has all but been destroyed by a meta-analysis published in mid-2007 and despite GlaxoSmithKline publishing positive data from the RECORD clinical trial in 2009 the drug will not regain market share before its patent expiry.
Key reasons to purchase this title
- Quantify the future size of the antidiabetics market and identify opportunities for new products.
- Learn how product expiries will shape the antidiabetics market.
- Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.
Source: Datamonitor